ArticleClinical kidney journal2025
The prevalence of immunoglobulin A nephropathy in the European Union and the impact of the COVID-19 pandemic: an estimation approach utilizing the kidney biopsy frequency.
Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The prevalence of IgA nephropathy in Japan: results from a nationwide survey.Clinical and experimental nephrology · 2026Article
- IgA Nephropathy: Epidemiology, Outcomes, and Insights for Primary Glomerulonephritides.Journal of clinical medicine · 2026Review
- The 2025 KDIGO IgA nephropathy guideline update: an ERA Immunonephrology Working Group perspective.Clinical kidney journal · 2025Article
- Lived Experiences of Patients and Care Providers in Focal Segmental Glomerular Sclerosis and IgA Nephropathy.Glomerular diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunoglobulin A nephropathy (IgAN) is the most common type of primary glomerulonephritis, requiring a kidney biopsy for diagnosis. This study aimed to estimate the prevalence of primary IgAN within the European Union (EU) and investigate the potential impact of the coronavirus disease 2019 (COVID-19) pandemic on kidney biopsy rates and IgAN diagnosis frequency. Methods: We conducted four comprehensive literature searches to identify data on the IgAN prevalence and incidence, native kidney biopsy rates and COVID-19 impact on these metrics. We calculated country-specific prevalence estimates based on a combination of published and modeled data, incorporating biopsy frequency and the Healthcare Access and Quality Index (HAQI). The EU IgAN prevalence was derived from country-specific prevalence estimates weighted by population size. Results: The estimated prevalence of IgAN in the EU was 4.31 per 10 000 population, with large geographic variation among countries, ranging from 0.16 to 14.4 per 10 000 population. A strong correlation was observed between the IgAN incidence and biopsy rate (R Conclusion: Our findings confirm the rarity of IgAN, albeit the most common type of glomerulonephritis. They underscore a robust correlation between biopsy rates and IgAN incidence, influenced by healthcare access and quality. The COVID-19 pandemic's temporary suppression of biopsy rates in 2020 suggests potential delays in IgAN diagnosis, warranting further investigation into the long-term effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.